Structural Heart Devices Market

Structural Heart Devices Market Overview

The structural heart devices market is witnessing substantial growth as the global burden of cardiovascular and valvular diseases rises and minimally invasive cardiac procedures gain wider acceptance. According to DelveInsight, the market was valued at USD 12.94 billion in 2025 and is anticipated to reach USD 30.62 billion by 2034, registering a CAGR of 10.08% from 2026 to 2034. Increasing demand for advanced cardiac repair and replacement solutions, technological progress, improved treatment outcomes, and expanding adoption of transcatheter procedures are expected to remain key contributors to market expansion.

Structural heart devices are developed to correct abnormalities affecting the heart valves, chambers, walls, and related anatomical structures. The product landscape includes repair solutions such as occluders, annuloplasty systems, and valvuloplasty devices, alongside replacement products such as mechanical and biological heart valves. By providing less invasive alternatives to traditional open-heart surgery, these technologies can be particularly valuable for elderly individuals and patients considered unsuitable for conventional surgery.

Rising Cardiovascular Disease Burden Driving Structural Heart Devices Market Expansion

The increasing prevalence of structural and valvular heart diseases continues to create significant demand for corrective cardiac interventions. Aortic valve stenosis affects millions of people globally, while mitral regurgitation represents another major disease burden. Congenital heart conditions, including atrial septal defects, ventricular septal defects, and patent foramen ovale, further contribute to the need for structural heart procedures.

Population aging is also increasing the number of individuals vulnerable to degenerative valve disorders. At the same time, conditions such as hypertension, obesity, and diabetes are adding to cardiovascular risk. Because untreated structural heart abnormalities may result in heart failure, arrhythmias, pulmonary hypertension, and other serious complications, earlier diagnosis and timely intervention are becoming increasingly important.

Technological Innovation Reshaping Structural Heart Devices Market Procedures

Rapid innovation in transcatheter technologies is changing how structural heart diseases are treated. Next-generation transcatheter heart valves, minimally invasive mitral and tricuspid repair systems, advanced annuloplasty solutions, and left atrial appendage closure devices are expanding the range of available treatment options.

Progress in cardiac imaging is also contributing to procedural improvements. Three-dimensional echocardiography, advanced imaging platforms, and artificial intelligence-assisted procedural guidance can help clinicians improve anatomical assessment and procedural accuracy. These advances are supporting treatment for patients with increasingly complex anatomies while potentially reducing surgical trauma, hospitalization, and recovery periods.

The growing acceptance of transcatheter aortic valve replacement has become a major factor in the evolution of structural heart care. TAVR is well established for many high-risk and intermediate-risk patients and is increasingly being evaluated for selected lower-risk populations. At the same time, transcatheter approaches for mitral and tricuspid valve repair and replacement continue to gain clinical relevance.